---
title: The landscape of MHC-presented phosphopeptides yields actionable shared tumor
  antigens for cancer immunotherapy across multiple HLA alleles
date: '2023-09-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37775115/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230930180856&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Phosphopeptides presented by multiple alleles that are
  differentially expressed on tumors constitute tumor-specific antigens that could
  be targeted for cancer immunotherapy, but the immunogenicity of such phosphopeptides
  is not a general feature. In particular, phosphopeptides presented by HLA-A*02:01
  and A*11:01 exhibit consistent immunogenicity, while phosphopeptides presented by
  HLA-A*03:01 and C*07:01, although appropriately presented, are not immunogenic.
  Thus, to address ...'
disable_comments: true
---
CONCLUSIONS: Phosphopeptides presented by multiple alleles that are differentially expressed on tumors constitute tumor-specific antigens that could be targeted for cancer immunotherapy, but the immunogenicity of such phosphopeptides is not a general feature. In particular, phosphopeptides presented by HLA-A*02:01 and A*11:01 exhibit consistent immunogenicity, while phosphopeptides presented by HLA-A*03:01 and C*07:01, although appropriately presented, are not immunogenic. Thus, to address ...